Valter C Lima

Summary

Country: Brazil

Publications

  1. ncbi [Coronary angiography and angioplasty in diabetic patients]
    Valter C Lima
    Disciplina de Cardiologia, EPM, UNIFESP, and Serviço de Hemodinâmica e Cardiologia Intervencionista do Hospital São Paulo, SP, Brazil
    Arq Bras Endocrinol Metabol 51:299-304. 2007
  2. ncbi Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system
    Valter C Lima
    Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista, Sao Paulo, SP, Brazil
    Arq Bras Cardiol 87:e162-7. 2006
  3. ncbi Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial
    Pedro A Lemos
    Heart Institute InCor, University of São Paulo Medical School USP, Sao Paulo, Brazil
    EuroIntervention 8:117-9. 2012
  4. ncbi Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial
    Pedro A Lemos
    Catheterization Laboratory, Heart Institute InCor, University of São Paulo Medical School USP, Sao Paulo, Brazil
    Catheter Cardiovasc Interv 74:665-73. 2009
  5. ncbi [Prevalence of coronary artery disease in type I diabetic candidates for double transplantation (kidney and pancreas)]
    Dinaldo C Oliveira
    , UNIFESP, , SP
    Arq Bras Cardiol 84:108-10. 2005
  6. ncbi Clinical outcome of renal transplant patients after coronary stenting
    Fábio Monteiro Mota
    Hospital do Rim e Hipertensao, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
    Arq Bras Cardiol 88:521-4. 2007
  7. ncbi Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients
    J Airton Arruda
    , , , , SP, Brazil 04024-002
    Am J Cardiol 91:1363-5. 2003
  8. ncbi Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia
    Fabio S Brito
    Hospital São Paulo and Hospital do Rim e Hipertensão, Federal University of Sao Paulo, Brazil
    Catheter Cardiovasc Interv 64:413-8. 2005
  9. ncbi [Tracking, diagnosis and revascularization of coronary arterial disease in type 2 diabetes: supreme challenges to contemporary medicine, also in Brazil!]
    Valter C Lima
    Arq Bras Endocrinol Metabol 50:1-3. 2006

Collaborators

  • Fabio S Brito
  • Pedro A Lemos
  • Marco A Costa
  • Fábio Monteiro Mota
  • Dinaldo C Oliveira
  • Jose O M Pestana
  • J Airton Arruda
  • Juliana Araújo
  • José Marconi A de Sousa
  • José Airton Arruda
  • Hélio T S Júnior
  • Francival L Souza
  • Alysson Nakamoto
  • Erika P Ribeiro
  • Adriano H P Barbosa

Detail Information

Publications9

  1. ncbi [Coronary angiography and angioplasty in diabetic patients]
    Valter C Lima
    Disciplina de Cardiologia, EPM, UNIFESP, and Serviço de Hemodinâmica e Cardiologia Intervencionista do Hospital São Paulo, SP, Brazil
    Arq Bras Endocrinol Metabol 51:299-304. 2007
    ..Conditions that favor surgery: long lesions, lesions in small vessels, presence of left anterior descending artery disease and need for associated valve surgery...
  2. ncbi Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system
    Valter C Lima
    Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista, Sao Paulo, SP, Brazil
    Arq Bras Cardiol 87:e162-7. 2006
    ....
  3. ncbi Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial
    Pedro A Lemos
    Heart Institute InCor, University of São Paulo Medical School USP, Sao Paulo, Brazil
    EuroIntervention 8:117-9. 2012
    ..The long-term clinical performance of drug-eluting stents (DES) coated with biodegradable polymers is poorly known...
  4. ncbi Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial
    Pedro A Lemos
    Catheterization Laboratory, Heart Institute InCor, University of São Paulo Medical School USP, Sao Paulo, Brazil
    Catheter Cardiovasc Interv 74:665-73. 2009
    ..The DES differed by the drug, but were identical otherwise, allowing to compare the anti-restenosis effects of sirolimus versus paclitaxel (secondary objective)...
  5. ncbi [Prevalence of coronary artery disease in type I diabetic candidates for double transplantation (kidney and pancreas)]
    Dinaldo C Oliveira
    , UNIFESP, , SP
    Arq Bras Cardiol 84:108-10. 2005
    ..CONCLUSION: Patients with type I diabetes in a dialysis program and candidates for double transplantation had an elevated prevalence of coronary artery disease. It is worth noting that those patients had no symptoms of the disease...
  6. ncbi Clinical outcome of renal transplant patients after coronary stenting
    Fábio Monteiro Mota
    Hospital do Rim e Hipertensao, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
    Arq Bras Cardiol 88:521-4. 2007
    ..To assess the clinical outcome of renal transplant patients who developed coronary artery disease and were treated with coronary stenting (TCA-ST)...
  7. ncbi Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients
    J Airton Arruda
    , , , , SP, Brazil 04024-002
    Am J Cardiol 91:1363-5. 2003
  8. ncbi Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia
    Fabio S Brito
    Hospital São Paulo and Hospital do Rim e Hipertensão, Federal University of Sao Paulo, Brazil
    Catheter Cardiovasc Interv 64:413-8. 2005
    ..2%) target vessel revascularizations. In conclusion, in this small group of high-risk ISR patients, oral sirolimus inhibited NIH and therefore may be an effective strategy for the prevention and treatment of ISR...
  9. ncbi [Tracking, diagnosis and revascularization of coronary arterial disease in type 2 diabetes: supreme challenges to contemporary medicine, also in Brazil!]
    Valter C Lima
    Arq Bras Endocrinol Metabol 50:1-3. 2006